

**Loss of Function in Escherichia coli exposed to Environmentally Relevant Concentrations of Benzalkonium Chloride**

FORBES, Sarah <<http://orcid.org/0000-0002-8361-6390>>, MORGAN, Nicola, HUMPHREYS, Gavin J. <<http://orcid.org/0000-0002-9138-0859>>, AMÉZQUITA, Alejandro, MISTRY, Hitesh and MCBAIN, Andrew J. <<http://orcid.org/0000-0002-5255-5425>>

Available from Sheffield Hallam University Research Archive (SHURA) at:  
<https://shura.shu.ac.uk/23691/>

---

This document is the

**Citation:**

FORBES, Sarah, MORGAN, Nicola, HUMPHREYS, Gavin J., AMÉZQUITA, Alejandro, MISTRY, Hitesh and MCBAIN, Andrew J. (2018). Loss of Function in Escherichia coli exposed to Environmentally Relevant Concentrations of Benzalkonium Chloride. Applied and environmental microbiology. [Article]

---

**Copyright and re-use policy**

See <http://shura.shu.ac.uk/information.html>

1                   **Loss of Function in *Escherichia coli* exposed to**  
2                   **Environmentally Relevant Concentrations**  
3                   **of Benzalkonium Chloride**

4  
5                   Sarah Forbes<sup>1</sup>, Nicola Morgan<sup>2</sup>, Gavin J Humphreys<sup>2</sup>,  
6                   Alejandro Amézquita<sup>3</sup>, Hitesh Mistry and Andrew J McBain<sup>2\*</sup>

7  
8                   <sup>1</sup>Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield. <sup>2</sup>Division of  
9                   Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health,  
10                  Stopford Building, The University of Manchester, Manchester, UK <sup>3</sup>Unilever, Safety and  
11                  Environmental Assurance Centre, Colworth Science Park,  
12                  Sharnbrook, Bedfordshire, MK44 1LQ, UK.  
13

14  
  
15  
16                  Running Title: *Escherichia coli* adaptation to residual concentrations of benzalkonium chloride  
17                  Key Words: Biocide, Bacteria, benzalkonium chloride.

18  
19  
  
20  
  
21  
  
22  
  
23  
  
24  
  
25  
  
26  
  
27  
  
28                  \*For correspondence: Andrew J McBain, Division of Pharmacy and Optometry, Faculty of Biology,  
29                  Medicine and Health, The University of Manchester, Oxford Road, Manchester M13 9PT, UK. Tel: 44  
30                  161 275 2360; Email: andrew.mcbain@manchester.ac.uk  
31

## 32 **ABSTRACT**

33 Assessing the risk of resistance associated with biocide exposure commonly involves exposing  
34 microorganisms to biocides at concentrations close to the MIC. With the aim of representing  
35 exposure to environmental biocide residues, *Escherichia coli* MG1655 was grown for 20  
36 passages in the presence or absence of benzalkonium chloride (BAC) at 100 ng/L and 1000  
37 ng/L (0.0002% and 0.002% of the MIC respectively). BAC susceptibility, planktonic growth  
38 rates, motility and biofilm-formation were assessed, and differentially expressed genes  
39 determined via RNA-sequencing. Planktonic growth rate and biofilm-formation were  
40 significantly reduced ( $p < 0.001$ ) following BAC adaptation, whilst BAC minimum bactericidal  
41 concentration increased two-fold. Transcriptomic analysis identified 289 upregulated and 391  
42 downregulated genes after long-term BAC adaptation when compared to the respective control  
43 organism passaged in BAC-free-media. When the BAC-adapted bacterium was grown in  
44 biocide-free medium, 1052 genes were upregulated and 753 were down regulated. Repeated  
45 passage solely in biocide-free medium resulted in 460 upregulated and 476 downregulated  
46 genes compared to unexposed bacteria. Long-term exposure to environmentally relevant BAC  
47 concentrations increased the expression of genes associated with efflux and reduced gene  
48 expression associated with outer-membrane porins, motility and chemotaxis. This was  
49 manifested phenotypically through loss-of-function (motility). Repeated passage in a BAC-  
50 free-environment resulted in the up-regulation of multiple respiration-associated genes, which  
51 was reflected by increased growth rate. In summary, repeated exposure of *E. coli* to BAC  
52 residues resulted in significant alterations in global gene expression that were associated with  
53 minor decreases in biocide susceptibility, reductions in growth-rate and biofilm-formation, and  
54 loss of motility.

55 **IMPORTANCE.** Exposure to very low concentrations of biocide in the environment is a  
56 poorly understood risk factor for antimicrobial resistance. Repeated exposure to trace levels of  
57 the biocide BAC resulted in loss of function (motility) and a general reduction in bacterial  
58 fitness, but relatively minor decreases in susceptibility. These changes were accompanied by  
59 widespread changes in the *E. coli* transcriptome. This demonstrates the importance of including  
60 phenotypic characterisation in studies designed to assess the risks of biocide exposure.

61

## 62 **INTRODUCTION**

63 Benzalkonium chloride (BAC) is a broad-spectrum quaternary ammonium biocide (1), which has a  
64 variety of applications in antiseptics, disinfection or preservation in industrial (2-4), medical (5)  
65 (6-8) and domestic (9-11) fields. Interest in the biological mechanisms that underpin the  
66 antibacterial mode of action of BAC has been longstanding (12). There is concern that biocides  
67 could select for reduced susceptibility in bacteria (13-15), which may occur through the

68 increased expression of efflux pumps (16-17), changes in cell permeability (18) or modification  
69 of cell surface electrostatic charge (17) (19). The potential for this to occur has been  
70 demonstrated through *in vitro* studies (20) but less so in environmental surveys (as previously  
71 reviewed (21)).

72 Regardless of the application, microorganisms are likely to be exposed to effective  
73 concentrations of biocides at the point of primary application and to lower concentrations  
74 through secondary exposure. This may result in a microorganism being exposed to  
75 concentrations of biocides that are substantially above the minimum bactericidal concentration,  
76 or anywhere on a continuum between this and zero, as previously reviewed (22) (13) (21) (23).

77 Biocide residues are commonly detected in aquatic environments with concentrations in the  
78 region of 100 ng/L reported in wastewater effluents (24) that will be further diluted as effluents  
79 are dissipated into the riverine and marine environments (25). Such biocide concentrations are  
80 several hundred times lower than MICs and could therefore be assumed to exert minimal  
81 selective pressure on exposed microbial populations.

82 The fact that environmentally relevant concentrations of biocides are likely to be considerably  
83 below those required to inhibit microbial growth has significance for risk assessment where *in*  
84 *vitro* testing has an important role (26-27). In such *in vitro* testing microorganisms are  
85 generally exposed to the biocides at sub-lethal concentrations. Concentrations used at the point  
86 of primary deployment are however often considerably higher than minimum bactericidal  
87 concentrations (14) (28).

88 We have previously assessed the effect of formulation (29-30), growth in taxonomically  
89 diverse biofilm communities (31), and potential impairment of fitness in biocide-adapted  
90 bacteria (32-33) in a series of studies intended to develop and apply methods for assessing the  
91 risk of biocide resistance based more closely on real-life conditions.

92 The current investigation considers biocide concentration as the variable of interest. We  
93 exposed *E. coli* to concentrations of BAC representing environmental residues in treated  
94 effluent, riverine and other environments (24). Antimicrobial susceptibility and phenotypic  
95 variables of relevance to environmental fitness and persistence were assessed. With the aim of  
96 correlating phenotypic changes with omics data, the transcriptomes of bacteria exhibiting loss  
97 of function following exposure to 100 ng/L BAC were profiled using RNA sequencing (RNA-  
98 seq).

## 99 **RESULTS**

100 *E. coli* was adapted to BAC at 100 ng/L and 1000 ng/L over 10 and 20 passages.  
101 Susceptibility (MIC and MBC) and planktonic and biofilm growth dynamics were assessed  
102 before and after adaptation and compared to the respective bacterium passaged in BAC-free  
103 medium. Alterations in the transcriptome were assessed using RNA-seq for BAC-adapted and  
104 non-adapted bacteria, following immediate growth in BAC-containing or BAC-free medium to  
105 determine the stability of any transcriptomic changes once the biocide was removed.

106 **Effects of BAC exposure on antimicrobial susceptibility.** No change in susceptibility  
107 (MIC or MBC) to BAC was observed after 10 passages in the presence of BAC at either  
108 concentration. The MBC increased two-fold (the minimum detectable change) for both  
109 exposure concentrations after 20 passages, whilst the MIC remained unchanged.

110 **Alterations in planktonic growth and biofilm formation after BAC exposure.**  
111 Repeated passage in biocide-free medium led to reduced lag phase, increased growth rate and  
112 decreased maximum culture density ( $p < 0.001$ ). Following adaptation (10 and 20 passages) with  
113 100 ng/L BAC, growth rates did not change but maximum culture densities were significantly  
114 decreased. Adaptation to 1000 ng/L of BAC (10 and 20 passages) also resulted in significantly  
115 decreased maximum culture densities but did not alter growth rates relative to the control.

116 However, lag phase increased following 10 passages with BAC at 1000 ng/L, which was not  
117 the case following 20 passages.

118 Repeated passage of bacteria solely in biocide-free medium resulted in significantly decreased  
119 biofilm formation when compared to unexposed parent bacterium ( $p < 0.05$ ). Adaptation to BAC  
120 at 100 or 1000 ng/L resulted in significantly greater reductions in biofilm formation ( $p < 0.05$ )  
121 (Figure 2). Biofilm formation was significantly ( $p < 0.05$ ) lower following 10 passages in the  
122 presence of BAC at 1000 ng/l compared to the equivalent number of passages at 100 ng/L  
123 although there was no significant difference in biofilm formation between treatment  
124 concentrations following 20 passages.

125 **Effect of BAC adaptation and exposure on the transcriptome.** Transcriptome  
126 analysis by RNA-seq was used to compare the effects of passaging bacteria 20 times in the  
127 presence of 100 ng/L of BAC (B (P20)) to a control organism, passaged 20 times in a BAC free  
128 environment (C (P20)). Bacteria were grown in the presence (PR) or absence of BAC prior to  
129 RNA extraction to determine the stability of any transcriptional adaptations towards the biocide  
130 once it was removed from the growth medium. The effects of immediate BAC exposure on the  
131 unexposed parent bacterium (C (P0)) and the effect of repeatedly passaging the parent  
132 bacterium in BAC-free growth media (C (P20)) were also evaluated. Differential expression  
133 analysis was conducted in the following pairwise comparisons; C (P0) v C (P20), C (P20) v B  
134 (P20), C (P20)-PR v B (P20)-PR and C (P0) v C (P0)-PR. BAC exposed bacteria were therefore  
135 compared to their respective control, with regards to number of passages performed.  
136 Transcription profiles for the untreated/unpassaged control bacterium C0 when grown in the  
137 immediate presence of 100 ng/L of BAC (C (P0)-PR) showed little variation, with a single gene  
138 being upregulated and two downregulated. In contrast for C (P0) v C (P20), representing  
139 continuous growth in BAC-free medium, 460 genes were upregulated and 476 were down  
140 regulated. For B (P20) (20 passages in 100 ng/ L of BAC) v C (P20) (20-passage control)

141 grown in the absence of BAC prior to RNA extraction, 1052 genes were upregulated and 753  
142 were down regulated. When the same bacteria were maintained in the presence of BAC prior to  
143 extraction, 289 DE genes were upregulated and 391 were down regulated (Supplementary  
144 material). Figure 3, a PCA plot of log<sub>2</sub> count data from all libraries for the second and third  
145 components indicates that C (P0), C (P20) and B (P20) are clearly separated reflecting distinct  
146 differences in gene expression profiles. Figure 3 indicates that growing bacteria in the presence  
147 of 100 ng/L of BAC had a lesser effect on gene expression than the effects of repeated BAC  
148 exposure over a longer period.

149 Growing the unexposed *E. coli* parent strain (C (P0)) in the presence of BAC (C (P0)-PR)  
150 resulted in a minor -1.12 log fold-decrease in *grxA* encoding glutaredoxin-1 which catalyzes the  
151 reduction of protein disulfides. A -0.9 log fold change in *rsbA* and a 0.9 log fold-change in  
152 *mgtA* were also observed, which are involved in ribose transport and peptidoglycan  
153 biosynthesis, respectively. Data in Tables 2-5 show data for differentially expressed genes  
154 associated with electron transport, cell permeability and efflux, motility and chemotaxis data  
155 for other genes are in Supplementary material. When repeatedly passaged in a BAC-free  
156 environment (C (P20)) an increase in the transcription of genes involved in respiration and  
157 generalised protein synthesis occurred compared to the unexposed parent strain (C (P0); Table  
158 2). In terms of respiration, there was a substantial increase (log 3.4 to 5-fold-change) in  
159 transcription of the cytochrome o oxidase complex encoded by *cyoABCDE*. Similarly, there  
160 was an increase (log 2.7 to 4.2-fold) in formate dehydrogenase O (FDH-O) a heterotrimeric  
161 complex encoded by *fdoG* ( $\alpha$ -subunit), *fdoH* ( $\beta$ -subunit) and *fdoI* ( $\gamma$ -subunit). A log 1.8 to 3.3-  
162 fold-increase in genes *nuoA* to *nuoN* encoding an NADH:ubiquinone oxidoreductase was also  
163 observed after repeated passage in binary culture in a BAC free environment. When passaged  
164 in the presence of BAC (B (20)), increases in these respiratory enzymes were not observed,  
165 with transcriptional reductions evident in *cyo*, *fdo* and *nuo* genes in comparison to the

166 respective passage control C20 (Table 2). Whilst repeated passage in the absence of BAC lead  
167 to an overall increase in the transcription of 50S Rpl and 30 S Rps ribosomal proteins  
168 (Supplementary Table 1), passaging in the presence of BAC (B20) caused a reduction in the  
169 transcription of these proteins relative to the BAC-free control (C (P20)). A significant  
170 upregulation in proteins associated with cellular efflux occurred after BAC exposure including  
171 MdtEF and MdtNOP, in addition to multi-drug resistance genes MdtG, MdtL, MdtM and MdtQ  
172 (Table 3). An increase in genes associated with the predicted Yhi efflux system (*yhiD*, *yhiJ*,  
173 *yhiM*, *yhiL* and *yhiS*,) was also observed (Table 3). A reduction in transcription in a number of  
174 omp genes associated with outer-membrane permeability occurred when *E. coli* was passaged  
175 in the presence of BAC.

176

177 The transcription of multiple genes associated with motility and chemotaxis in *E. coli* was  
178 reduced following BAC adaptation, including the transcription factor *flhDC* a master regulator  
179 of a multi-tiered transcriptional network including genes responsible for flagella regulation,  
180 biosynthesis and assembly (*fli* and *flg*) in addition to the flagella motor complex proteins MotA  
181 and MotB. The down-regulation of these motility-associated genes was further enhanced in the  
182 presence of BAC prior to RNA extraction (Table 4). This reduction in motility was further  
183 confirmed using a triphenyltetrazolium chloride-based motility assay (Figure 4). Several genes  
184 associated with chemotaxis were downregulated after BAC exposure, including some within  
185 the Che family, which are associated with the transmission of sensory signals from  
186 chemoreceptors to the flagella motors (Table 5). Additionally, methyl-accepting  
187 chemoreceptors Tsr, Tar and signal transducer Tap were downregulated. The transcription of  
188 these chemotaxis associated proteins were further downregulated when bacteria were grown in  
189 the presence of BAC prior to RNA extraction (Table 5).

190

191 **DISCUSSION**

192 Used appropriately, biocides offer an important means of reducing the transmission and growth  
193 of microorganisms (34-36). They have the potential, through disinfection and antisepsis, to  
194 reduce the incidence of infections and the burden on antibiotics (37) (35) and to protect  
195 consumers through the preservation of liquid formulations (38).

196 Decisions on what constitutes appropriate biocide use and optimisation of current practices  
197 must be based on evidence. In this context, assessing the risks of resistance associated with  
198 biocide use relies mainly on data generated from environmental surveys or in the laboratory  
199 through the exposure of microorganisms to biocides. The former approach offers the possibility  
200 of determining susceptibility in exposed environments but directly linking susceptibility in  
201 exposed microbial populations to biocide exposure has been challenging (15) (39). Laboratory  
202 studies on the other hand enable the effects of biocide exposure to be determined, but are by  
203 definition artificial (40) since many factors associated with the biocide and the microorganisms  
204 in the laboratory do not necessarily closely reproduce the conditions of environmental exposure.  
205 These include the fact that *in vitro* studies most commonly involve the exposure of single-  
206 species, planktonic cultures of bacteria to biocides delivered in simple aqueous solution, at  
207 concentrations that have been selected to be sublethal, but are relatively close to MICs (20).  
208 There is therefore the potential to increase the realism in such studies and this has been done to  
209 a limited extent by introducing complex communities (28) and formulation (26) (29).

210 Concentration is a critical variable in determining the outcome of the exposure of a  
211 microorganism to an antimicrobial compound, since exposure to concentrations greater than the  
212 susceptibility of the exposed microorganism will lead to complete inhibition or inactivation,  
213 whilst exposure to various sub-lethal concentrations is more likely to be selective. It is  
214 necessary to use sub-lethal concentrations, that are mostly considerably lower than those used  
215 at the point of biocide application in experimental risk assessment since inactivated cultures

216 cannot adapt. However, concentrations utilized in many reports are relatively close to the MIC  
217 and as such best reflect a limited subset of environmental scenarios. In real-world use, biocides  
218 are variously eluted into aquatic environments through wastewater disposal systems (41) which  
219 is particularly relevant in risk assessment due to the high bacterial densities and taxonomic  
220 diversity in sewage treatment and aquatic environments, and the presence of biocides on a  
221 continuum between hundredths of the MIC to zero.

222 *E. coli* may be exposed in the environment to biocide concentration many times lower than  
223 would be required to inhibit growth (42) with poorly understood implications. In the current  
224 investigation therefore, the bacterium was exposed in the fluid-phase to environmentally  
225 relevant residual concentrations of the commonly used quaternary ammonium compound BAC.  
226 Biocide-free cultures were also assessed to control for general adaptation occurring during  
227 repeated growth on normal medium. Changes occurred following 20 passages with or without  
228 BAC. Susceptibility decreased two-fold after exposure to BAC residues (MBC) but not  
229 following growth in biocide-free conditions. Compared to bacteria grown in biocide-free  
230 conditions, which increased in planktonic growth rate and maximum culture density after  
231 adaption, BAC adapted bacteria were significantly less productive in terms of maximum  
232 culture density when grown in normal medium.

233 In previous reports, large changes in susceptibility have been reported following repeated or  
234 long-term exposure to relatively high concentrations of BAC (for example, 3 mg/L initial MIC  
235 to 90mg/L in *E. coli* (43) and for *Pseudomonas aeruginosa*, 50mg/L to 1,600 mg/L) (44-45).  
236 These susceptibility changes have been associated in various bacterial species, with reductions  
237 in cell permeability (46), increased expression of broad range efflux systems (47) and the  
238 induction of general stress response (48) although it is likely that several adaptation  
239 mechanisms will be involved during adaptation (43). Importantly however, in many previous

240 studies adapted bacteria were generated by exposure to BAC concentrations of up to 200 mg/L  
241 (17) (47) (49) over 1000 times higher than in the current study.

242 Repeated exposure BAC concentrations representing environmental residues resulted in  
243 considerably smaller reductions in susceptibility than the majority of previous reports. The  
244 MBC of the unexposed bacterium was 50 µg/ml and no change occurred after 10 passages with  
245 100 or 1000 ng/L BAC. By 20 passages only a two-fold decrease in susceptibility occurred.  
246 Significant changes were however observed in biofilm formation in adapted bacteria. Whilst  
247 planktonic passage in biocide-free conditions reduced biofilm accumulation, BAC adapted  
248 organisms were further suppressed in biofilm formation and following 20 passages with BAC  
249 residues, adapted bacteria became non-motile. Thus, exposure to concentrations of BAC  
250 representing environmental residues was associated with reduction in function (growth rate and  
251 biofilm formation) and loss of function (motility), whilst by comparison, passage in normal  
252 medium increased planktonic fitness.

253 With respect to RNAseq data, passage in biocide-free medium alone (C (P20)) resulted in 460  
254 upregulated and 476 downregulated genes compared to the unpassed parent bacterium (C  
255 P0)). Long-term exposure to environmentally relevant BAC concentrations (B (P20)) increased  
256 transcription of efflux proteins and led to a reduction in outer-membrane porins and genes  
257 associated with motility and chemotaxis, which was manifested phenotypically through loss-of-  
258 function (motility). Repeated passage of control cultures in a BAC-free-environment resulted in  
259 the up-regulation of multiple respiration-associated proteins, which was reflected by increases  
260 in planktonic growth rates. Thus, repeated exposure of *E. coli* to BAC residues resulted in  
261 significant alterations in global gene expression that were associated with marginal decreases in  
262 biocide susceptibility, reductions in growth-rate and biofilm-formation, and loss of function for  
263 motility.

264 The minor decreases in susceptibility observed in BAC-adapted bacteria are potentially  
265 attributable to the down-regulation of outer membrane proteins and upregulation of proposed  
266 efflux systems, as observed in the transcriptomic data. This agrees with previous reports  
267 documenting the adaptive BAC insusceptibility in *E. coli*, where microarray analysis indicated  
268 the involvement of active efflux (43). In contrast to previous reports however, significant  
269 upregulation of the *acrAB* efflux system or the outer membrane protein TolC was not observed  
270 and there was no significant increase in the transcription of stress response systems, such as  
271 those belonging to the *soxRS* regulon, or the multiple antibiotic resistance operon *MarA* (50-  
272 51). An increase in transcription of genes associated with the Mdt and Yhi efflux systems was  
273 however observed which could further explain the minor changes in BAC susceptibility.

274 Increases in the transcription of genes associated with cellular respiration and protein synthesis  
275 were observed following adaptation to BAC-free environment. Since the bacteria are actively  
276 growing, this observed increase in cellular activity may represent adaption to the conditions of  
277 rapid growth on laboratory media. This increase did not occur following adaptation to BAC,  
278 possibly due to the inhibitory effect of BAC on respiratory processes or the associated  
279 metabolic burden as evidenced by data presented in Figure 1 associated with damage to the cell  
280 membrane and potentially impaired function of associated cell membrane bound proteins  
281 impacting electron transport (52).

282 The effect of adaptation to BAC on motility and chemotaxis in was particularly notable since it  
283 resulted in loss of motility. In terms of mechanisms responsible, flagella and motility-  
284 associated proteins were down regulated in response to BAC exposure. Flagella are widely  
285 documented virulence factors in *E. coli* and have been previously suggested to play a key role  
286 in biofilm formation (53-54) . Thus, a decrease in flagella expression, in addition to the down-  
287 regulation in the transcription of various chemotaxis related proteins, could account for the  
288 decrease in biofilm formation observed after BAC exposure (Figure 2).

289 In summary, concentrations of BAC representing environmental residues induced minor  
290 changes in antimicrobial susceptibility in *E. coli* that were associated with a decrease in outer  
291 membrane proteins and up-regulation of efflux systems. Cellular respiration associated proteins  
292 were transcriptionally down regulated, and planktonic growth rates reduced following BAC  
293 adaptation. BAC adaptation also resulted in a significant decrease in motility and biofilm  
294 formation, possibly due to a decrease in the transcription of proteins involved in flagella  
295 synthesis, function and chemotaxis in the bacterial cell. The combination of phenotypic and  
296 transcriptomic analysis presents the opportunity to consider the two distinct approaches in the  
297 context of risk assessment. Omics and molecular genetics are increasingly applied in this field  
298 (17, 55) and in some cases have indicated potential changes of concern associated with biocide  
299 exposure; for example virulence potential (56) and transfer of genes associated with resistance  
300 (57). Determining the biological or real-world significance of such data without phenotypic  
301 corroboration can be problematic, and this is of concern where the objective is diligent risk  
302 assessment to inform product composition. Thus, more work is required before genotype-  
303 phenotype relationships can be effectively integrated in to the process of risk assessment.  
304 Similarly, genome-wide association studies, applied with the aim of predicting antibiotic  
305 resistance (58) may be less successful when applied to biocide studies due to the complexity of  
306 modes of action and resistance mechanisms.

307 Data generated in the current investigation suggest that despite the differences in gene  
308 expression profiles, endpoints of relevance for decision-making (i.e. reduced biocide  
309 susceptibility) remained practically unchanged. Had the study generated only transcriptomic  
310 data, the message of relevance to risk assessment would probably be different (e.g.  
311 overexpression of efflux pumps). This investigation therefore highlights the importance of  
312 utilising phenotypic analysis to supplement transcriptome profiling when assessing functional  
313 consequence and determining risk assessment of biocide usage in bacteria.

314

315

## 316 **METHODS**

317 **Bacteria, bacteriological media and antimicrobial agents.** *E. coli* MG1655 was  
318 selected a well-characterized example of this bacterium, for which whole genome sequence  
319 data are available. The bacterium, and growth media were purchased from Oxoid (Basingstoke,  
320 United Kingdom). The bacterial growth medium was sterilized at 121°C and 15 lb/in<sup>2</sup> for 15  
321 min prior to use. *E. coli* was grown on Tryptone Soy Agar and Tryptone Soy Broth. BAC  
322 ( $\geq 95.0\%$ ) was purchased from Sigma-Aldrich (Dorset, United Kingdom) and was prepared at 1  
323 mg/ml in deionised water and filter sterilised (0.2  $\mu$ M pore size) prior to use.

324 **Determination of MICs and MBCs.** MICs were determined by microdilution  
325 according to EUCAST methods ([https://onlinelibrary.wiley.com/doi/pdf/10.1046-j.1469-0691.2003.00790.x](https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1469-0691.2003.00790.x)) using TSB as growth medium. BAC concentrations ranged between 0.8  
326 and 800  $\mu$ g/ml. Growth was determined through turbidity (OD<sub>600</sub>) compared to uninoculated  
327 wells (negative control) using a microtiter plate reader (PowerWave XS, BioTek, Bedfordshire,  
328 United Kingdom).

330 Minimum bactericidal concentrations were determined as described previously (14, 59).  
331 Briefly, aliquots (10  $\mu$ l) from wells exhibiting no turbidity were transferred to sterile TSA prior  
332 to 4 days of incubation at 37°C to determine the MBC. The MBC was defined as the lowest  
333 concentration of biocide at which no growth occurred after 4 days of incubation.

334 **Planktonic growth rate.** Overnight cultures of *E. coli* were diluted to an OD<sub>600</sub> of 0.8  
335 then further diluted 1:100 in TSB in the presence and absence of 100 or 1000 ng/L BAC.  
336 Bacteria were incubated in 96 well microtiter plates at 37°C for 24 h and the OD<sub>600</sub> was  
337 determined every hour spectrophotometrically.

338           **Crystal violet biofilm formation assay.** Overnight cultures of *E. coli* were diluted to  
339 an OD<sub>600</sub> of 0.8 then further diluted 1:100 in TSB. 150 µl of diluted bacterial inoculum was  
340 delivered to each test well of a 96-well microtiter plate prior to incubation for 48 h at 37 °C and  
341 20 rpm to promote biofilm growth. Wells were washed twice with 250 µl of sterile PBS before  
342 addition of 200 µl of 0.5% (w/v) crystal violet solution. Plates were incubated for 30 min at  
343 room temperature and the wells were subsequently washed twice with 250 µl of PBS and left to  
344 dry at room temperature for 1 h. Attached crystal violet was solubilised in 250 µl of 95%  
345 ethanol and plates were agitated at room temperature at 20 rpm for 1 h. After solubilisation,  
346 biofilm growth was viewed as change in OD<sub>600</sub> relative to a sterile negative control. Biofilm  
347 bound crystal violet was quantified and average values were calculated using data from two  
348 separate experiments each with three technical replicates. Statistical significance was  
349 determined using an ANOVA with Post-Hoc Tukey analysis where p<0.05 was deemed  
350 significant.

351           **Motility assay.** Single colonies of *E. coli* were stab inoculated into 10 ml of Remel™  
352 Motility Test Medium (Thermo Scientific, UK) containing 2,3,5-triphenyltetrazolium chloride.  
353 Tubes were incubated for 48 h at 37°C, growth was determined visually as the presence of a red  
354 pigment at the line of inoculation. Three biological replicates were done for each test bacterium.

355           **Repeated exposure to low levels of BAC.** Conical flasks containing 50 ml of TSB  
356 were set-up containing 100 or 1000 ng/ L of BAC. These concentrations were selected to  
357 represent residual concentrations that have been reported in natural aquatic environments and in  
358 wastewater (24-25). Overnight cultures of bacteria were diluted to 0.8 OD<sub>600</sub> then further  
359 diluted 1:100 into the BAC containing growth medium. Flasks were incubated at 37°C and 100  
360 rpm aerobically for 48 h. Bacteria were passaged 10 or 20 times in the presence of the biocide  
361 whilst using a consistent inoculation density for each passage (OD<sub>600</sub> 0.008; 3 - 5 x 10<sup>7</sup> cfu/ml).  
362 Cultures were plated between all passages to check for purity and viability. The progenitor

363 (control) strain that has not been passaged or exposed to BAC was designated “C (P0)”. For  
364 passaged bacteria “B” refers to the BAC concentration and “P” to the number of passages. Thus,  
365 “B100 (P20)” was grown on the presence of BAC at 100ng/L for 20 passages.

366 **RNA extraction.** RNA was extracted from 30 ml of a mid-log phase culture of the  
367 previously generated adapted bacteria of *E. coli* (OD<sub>600</sub>=0.2). Bacteria were grown in the  
368 presence or absence of 100 ng/L of BAC prior to extraction to determine the stability of any  
369 induced changes in gene expression once the BAC selective pressure was removed.  
370 Transcription was stopped using 3.6 ml of 5 % phenol in ethanol prior to the addition of 10 ml  
371 RNeasy Protect™ bacteria reagent (Qiagen, UK). Bacteria were pelleted at 4000 rpm for 15 mins.  
372 Bacterial pellets were resuspended in 1 ml of 0.5 % Tween 80 prior to re-pelleting at 4000 rpm  
373 for 15 mins. Pellets were resuspended in 200 µl of RNase free water and added to 750 µl of  
374 extraction buffer (0.5 M sodium acetate, 0.5 % SDS, pH 4). Resuspensions were transferred to  
375 1.5 ml lock top tubes containing sterile glass beads (sigma) and vortexed 10 x for 1 min with 10  
376 min cooling on ice in between vortexing. Liquid was removed from tubes and transferred to a  
377 sterile 1.5ml microcentrifuge tube containing 500 µl of phenol on ice before centrifugation for  
378 15 min at 13,000 rpm. The aqueous layer was removed from each tube and transferred to 1 ml  
379 of 100 % ethanol on ice containing 100 µl 3 M sodium acetate. RNA was then precipitated at -  
380 20°C for 30 min before centrifugation at 13,000 rpm for 15 min. Supernatant was subsequently  
381 removed and the pellet was washed in 1 ml of 80 % ethanol and air dried before dissolving in  
382 50 µl RNase free water. 5 µl of RNA was added to 5 µl of 2 x RNA gel loading dye  
383 (ThermoFisher Scientific, UK) and heated at 65°C for 10 min before being run at 45 V on a  
384 1 % agarose gel for 45 min to check RNA integrity. RNA was DNase treated (DNase1) for 30  
385 min at 37°C, quantified on a NanoDrop Microvolume Spectrophotometer (ThermoFisher, UK)  
386 prior to being sent to the Centre for Genomic Research at University of Liverpool for RNA-  
387 sequencing and analysis.

388           **RNA sequencing.** Samples were prepared for RNA sequencing using the Epicentre  
389 ScriptSeq Complete Bacterial kit with an input of 2000ng of RNA for ribosomal depletion.  
390 Ribosomal depleted samples were run on an Agilent Bioanalyzer to check for successful  
391 depletion of the ribosomal RNA. All purified depleted RNA was used in ScriptSeq v2 Library  
392 preparation according to manufacturer's instructions. Libraries were purified using AxyPrep  
393 Mag beads. Each library was quantified using Qubit and the size distribution assessed using the  
394 Agilent 2100 Bioanalyser. The 18 amplified libraries were multiplexed as a single pool. The  
395 pooled sample was further purified with AxyPrep Mag beads to remove small amount of  
396 adaptor in a few of the individual libraries. The template DNA was denatured according to the  
397 protocol described in the Illumina cBot User guide and loaded at 13 pM concentration. The  
398 sequencing was carried out on one lane of an Illumina HiSeq2500 at 2x125 bp paired-end  
399 sequencing with v4 chemistry. RNA sequencing and initial data analysis was done at The  
400 Centre for Genomic Research, University of Liverpool.

401           **Data processing and sequence alignment.** Base calling and de-multiplexing of  
402 indexed reads was done using by CASAVA version 1.8.2 (Illumina). The raw fastq files were  
403 trimmed to remove Illumina adapter sequences using Cutadapt version 1.2.1 (60). The reads  
404 were further trimmed to remove low quality bases using Sickle version 1.200, with a minimum  
405 window quality score of 20. Reads were aligned to the genome sequences using Bowtie2  
406 version 2.2.5 (61) (62). The option for read mate orientation was set as --fr and the other  
407 options were default.

408           **Differential expression analysis.** Gene expression was calculated from read alignment  
409 files using htseq-count (Simon et al., 2014). The count numbers were also converted into  
410 FPKM values. The count numbers per gene were put into differential expression analysis. The  
411 main processes of the analysis include data variation assessment, data modelling, model fitting,  
412 testing and DE genes detecting. All the DGE (Differential Gene Expression) analyses were

413 performed in R (version 3.2.2) environment using the edgeR (Robinson et al, 2010) package.  
414 With respect to the assessment of variation in the count data, the variation between samples  
415 within a sample group (within-group variation) is usually smaller than that between samples  
416 from different sample groups (overall variation) because the former consists of technical and  
417 biological variation only, while the latter also contains variation because of other factors. When  
418 the factor effect is the dominant term of variation, the sample groups can be clearly separated  
419 by using assessment tools. If the factor effect is weak compared to the technical and biological  
420 variation within sample groups will be difficult to be discriminated from the data. An  
421 assessment reveals that the within-group variation was strong for C0, C0P, B20 and B20P four  
422 sample groups. In each of them, one sample is not correlated closely with the other two samples  
423 of the same group. Whilst the C (P20) and C (P20)-PR two groups had obviously higher  
424 within-group correlation (see correlation heatmap Figure 2). The pairwise scatter plots of  $\log_{10}$   
425 count data of the samples for each group give the same view as the correlation heatmap. Two  
426 example figures are presented here: Figure 3 is the pairwise scatter plot for the C0 group, and  
427 Figure 4 is for the C20 group. Figure 5 is the PCA plot of  $\log_{10}$  count data from all libraries,  
428 the second and third components are plotted. The plot shows that the C (P0), C (P20) and B  
429 (P20) can be clearly separated; indicating the differences between them caused notable  
430 differences in gene expression. Comparatively, the impact of growing cells in the presence of  
431 BAC or not is relative weaker. Therefore, it is expected that more genes will be identified as  
432 DE from C (P0) vs C (P20) or C (P20) vs B (P20) or C (P20)-PR vs B (P20)-PR than from C  
433 (P0) vs C (P0)-PR.

434 **Statistical analyses.** Data from crystal violet biofilm formation assays were analyzed  
435 using a one-way ANOVA (analysis of variance) and post-hoc Tukey analysis.

436 To compare growth curves a non-linear regression analysis using the logistic model was used. As  
437 follows:

$$Y(t) = \frac{L}{(1 + e^{-k(t_{50}-t)})}$$

438  
439 The above growth law was used to analyse the following 3-way comparisons: C0 v C10 v C20, ii C0 v  
440 B100 (P10) v B100 (P20); iii) C0 v B1000 (P10) v B1000 (P20); iv) C10 v B100 (P10) v B1000 (P10)  
441 and v) C20 v B100 (P20) v B1000 (P20). For each comparison the following step-wise analysis  
442 procedure was used to assess experimental condition effects. The logistic model was fitted to all three  
443 conditions without accounting for the experimental condition. Subsequently parameter values were  
444 varied according to experimental condition type, therefore three L, k and t50 values representing each  
445 condition were estimated, and assessed whether this improved model fit using the F-test. To arrive at the  
446 final model, if the 95 percent confidence interval, generated using the profile likelihood, for the same  
447 parameter across the three conditions overlapped, then that parameter was grouped across conditions.  
448 Subsequently an assessment of the effect that had on model fit was conducted using the F-test and the  
449 new model accepted with a p-value threshold of 0.05. The resulting differences between treatments via  
450 model parameters were reported with 95 percent confidence intervals (CI). A P-value from the F-test  
451 was reported together with quantitative details, maximal growth and time to reach 50% of  
452 maximal growth, on how the growth curves differed.

453

#### 454 **ACKNOWLEDGMENTS**

455 A.A. is an employee of Unilever. The rest of us have no conflicts of interest to declare.  
456 S.F., A.A., and A.J.M. conceived and designed the experiments. S.F. and N.C. per- formed the  
457 experiments. S.F., N.C., G.H., A.A., and A.J.M. analyzed the data. H.M. performed the  
458 statistical modeling. S.F. and A.J.M. wrote the paper. This project was funded by Unilever's  
459 Safety and Environmental Assurance Centre (to AJM).

460

## 461 REFERENCES

- 462 1. **Furi L, Ciusa ML, Knight D, Di Lorenzo V, Tocci N, Cirasola D, Aragonés L,**  
463 **Coelho JR, Freitas AT, Marchi E, Moce L, Visa P, Northwood JB, Viti C, Borghi E,**  
464 **Orefici G, Consortium tB, Morrissey I, Oggioni MR.** 2013. Evaluation of Reduced  
465 Susceptibility to Quaternary Ammonium Compounds and Bisbiguanides in Clinical  
466 Isolates and Laboratory-Generated Mutants of *Staphylococcus aureus*. *Antimicrobial*  
467 *Agents and Chemotherapy* 57:3488-3497.
- 468 2. **Alzubeidi YS, Udombijitkul P, Talukdar PK, Sarker MR.** 2018. Inactivation of  
469 *Clostridium perfringens* spores adhered onto stainless steel surface by agents used in a  
470 clean-in-place procedure. *Int J Food Microbiol* 277:26-33.
- 471 3. **Condell O, Iversen C, Cooney S, Power KA, Walsh C, Burgess C, Fanning S.** 2012.  
472 Efficacy of biocides used in the modern food industry to control Salmonella-links  
473 between biocide tolerance and resistance to clinically relevant antimicrobial compounds.  
474 *Applied and Environmental Microbiology:AEM.* 07534-11.
- 475 4. **Jia R, Li Y, Al-Mahamedh HH, Gu T.** 2017. Enhanced Biocide Treatments with D-  
476 amino Acid Mixtures against a Biofilm Consortium from a Water Cooling Tower. *Front*  
477 *Microbiol* 8:1538.
- 478 5. **Uppal S, Bazzi A, Reynolds RK, Harris J, Pearlman MD, Campbell DA, Morgan**  
479 **DM.** 2017. Chlorhexidine-Alcohol Compared With Povidone-Iodine for Preoperative  
480 Topical Antisepsis for Abdominal Hysterectomy. *Obstet Gynecol* 130:319-327.
- 481 6. **Barbolt TA.** 2002. Chemistry and safety of triclosan, and its use as an antimicrobial  
482 coating on Coated VICRYL\* Plus Antibacterial Suture (coated polyglactin 910 suture  
483 with triclosan). *Surg Infect (Larchmt)* 3 Suppl 1:S45-53.
- 484 7. **Maki DG, Stolz SM, Wheeler S, Mermel LA.** 1997. Prevention of Central Venous  
485 Catheter-Related Bloodstream Infection by Use of an Antiseptic-Impregnated Catheter.  
486 *Annals of Internal Medicine* 127:257-266.
- 487 8. **Gaonkar TAP, Sampath LABA, Modak SMP.** 2003. Evaluation of the Antimicrobial  
488 Efficacy of Urinary Catheters Impregnated with Antiseptics in an In Vitro Urinary Tract  
489 Model. *Infection Control and Hospital Epidemiology* 24:506-513.
- 490 9. **Bloomfield SF.** 2002. Significance of biocide usage and antimicrobial resistance in  
491 domiciliary environments. *Symp Ser Soc Appl Microbiol*:144S-157S.
- 492 10. **Vander Heyde Y, Nguyet AN, Detaevenier MR, Massart DL, Plaizier-Vercammen**  
493 **J.** 2002. Simultaneous determination of ketoconazole and formaldehyde in a shampoo:  
494 liquid chromatography method development and validation. *J Chromatogr A* 958:191-  
495 201.
- 496 11. **Koehler DA, Strevett KA, Papelis C, Kibbey TCG.** 2017. The impact of antibacterial  
497 handsoap constituents on the dynamics of triclosan dissolution from dry sand.  
498 *Chemosphere* 186:251-256.
- 499 12. **Klimek JW, Bailey JH.** 1956. Factors influencing the rate of killing of *Escherichia coli*  
500 exposed to benzalkonium chloride. *Appl Microbiol* 4:53-9.
- 501 13. **McBain AJ, Gilbert P.** 2001. Biocide tolerance and the harbingers of doom.  
502 *International Biodeterioration & Biodegradation* 47:55-61.
- 503 14. **Moore LE, Ledder RG, Gilbert P, McBain AJ.** 2008. In vitro study of the effect of  
504 cationic biocides on bacterial population dynamics and susceptibility. *Appl Environ*  
505 *Microbiol* 74:4825-34.
- 506 15. **Marshall BM, Robleto E, Dumont T, Levy SB.** 2012. The frequency of antibiotic-  
507 resistant bacteria in homes differing in their use of surface antibacterial agents. *Curr*  
508 *Microbiol* 65:407-15.

- 509 16. **Chuanchuen R, Karkhoff-Schweizer RR, Schweizer HP.** 2003. High-level triclosan  
510 resistance in *Pseudomonas aeruginosa* is solely a result of efflux. *Am J Infect Control*  
511 31:124-7.
- 512 17. **Kim M, Hatt JK, Weigand MR, Krishnan R, Pavlostathis SG, Konstantinidis KT.**  
513 2018. Genomic and Transcriptomic Insights into How Bacteria Withstand High  
514 Concentrations of Benzalkonium Chloride Biocides. *Appl Environ Microbiol* 84.
- 515 18. **Jennings MC, Forman ME, Duggan SM, Minbiole KPC, Wuest WM.** 2017. Efflux  
516 Pumps Might Not Be the Major Drivers of QAC Resistance in Methicillin-Resistant  
517 *Staphylococcus aureus*. *Chembiochem* 18:1573-1577.
- 518 19. **Nagai K, Murata T, Ohta S, Zenda H, Ohnishi M, Hayashi T.** 2003. Two different  
519 mechanisms are involved in the extremely high-level benzalkonium chloride resistance  
520 of a *Pseudomonas fluorescens* strain. *Microbiology and immunology* 47:709-715.
- 521 20. **Mc Cay PH, Ocampo-Sosa AA, Fleming GT.** 2010. Effect of subinhibitory  
522 concentrations of benzalkonium chloride on the competitiveness of *Pseudomonas*  
523 *aeruginosa* grown in continuous culture. *Microbiology* 156:30-8.
- 524 21. **Gilbert P, McBain AJ.** 2003. Potential impact of increased use of biocides in consumer  
525 products on prevalence of antibiotic resistance. *Clin Microbiol Rev* 16:189-208.
- 526 22. **Gilbert P, Allison DG, McBain AJ.** 2002. Biofilms in vitro and in vivo: do singular  
527 mechanisms imply cross-resistance? *J Appl Microbiol* 92 Suppl:98S-110S.
- 528 23. **Russell AD.** 2003. Biocide use and antibiotic resistance: the relevance of laboratory  
529 findings to clinical and environmental situations. *Lancet Infect Dis* 3:794-803.
- 530 24. **Clara M, Scharf S, Scheffknecht C, Gans O.** 2007. Occurrence of selected surfactants  
531 in untreated and treated sewage. *Water Res* 41:4339-48.
- 532 25. **Grillitsch B, Gans O, Kreuzinger N, Scharf S, Uhl M, Fuerhacker M.** 2006.  
533 Environmental risk assessment for quaternary ammonium compounds: a case study  
534 from Austria. *Water Sci Technol* 54:111-8.
- 535 26. **Knapp L, Amezquita A, McClure P, Stewart S, Maillard JY.** 2015. Development of  
536 a protocol for predicting bacterial resistance to microbicides. *Appl Environ Microbiol*  
537 81:2652-9.
- 538 27. **Knapp L, Rushton L, Stapleton H, Sass A, Stewart S, Amezquita A, McClure P,**  
539 **Mahenthalingam E, Maillard JY.** 2013. The effect of cationic microbicide exposure  
540 against *Burkholderia cepacia* complex (BCC); the use of *Burkholderia lata* strain 383  
541 as a model bacterium. *J Appl Microbiol* 115:1117-26.
- 542 28. **McBain AJ, Ledder RG, Moore LE, Catrenich CE, Gilbert P.** 2004. Effects of  
543 quaternary-ammonium-based formulations on bacterial community dynamics and  
544 antimicrobial susceptibility. *Appl Environ Microbiol* 70:3449-56.
- 545 29. **Cowley NL, Forbes S, Amezquita A, McClure P, Humphreys GJ, McBain AJ.** 2015.  
546 Effects of Formulation on Microbicide Potency and Mitigation of the Development of  
547 Bacterial Insusceptibility. *Appl Environ Microbiol* 81:7330-8.
- 548 30. **Forbes S, Knight CG, Cowley NL, Amezquita A, McClure P, Humphreys G,**  
549 **McBain AJ.** 2016. Variable Effects of Exposure to Formulated Microbicides on  
550 Antibiotic Susceptibility in Firmicutes and Proteobacteria. *Appl Environ Microbiol*  
551 82:3591-3598.
- 552 31. **Forbes S, Cowley N, Humphreys G, Mistry H, Amezquita A, McBain AJ.** 2017.  
553 Formulation of Biocides Increases Antimicrobial Potency and Mitigates the Enrichment  
554 of Nonsusceptible Bacteria in Multispecies Biofilms. *Appl Environ Microbiol* 83.
- 555 32. **Latimer J, Forbes S, McBain AJ.** 2012. Attenuated virulence and biofilm formation in  
556 *Staphylococcus aureus* following sublethal exposure to triclosan. *Antimicrob Agents*  
557 *Chemother* 56:3092-100.


- 558 33. **Forbes S, Latimer J, Bazaid A, McBain AJ.** 2015. Altered Competitive Fitness,  
559 Antimicrobial Susceptibility, and Cellular Morphology in a Triclosan-Induced Small-  
560 Colony Variant of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 59:4809-16.
- 561 34. **Koski TA, Stuart LS, Ortenzio LF.** 1966. Comparison of chlorine, bromine, iodine as  
562 disinfectants for swimming pool water. *Appl Microbiol* 14:276-9.
- 563 35. **Harnoss JC, Assadian O, Kramer A, Probst P, Muller-Lantzsch C, Scheerer L,**  
564 **Bruckner T, Diener MK, Buchler MW, Ulrich AB.** 2018. Comparison of  
565 chlorhexidine-isopropanol with isopropanol skin antiseptics for prevention of surgical-  
566 site infection after abdominal surgery. *Br J Surg* 105:893-899.
- 567 36. **Garcia MT, Pelaz C.** 2008. Effectiveness of disinfectants used in cooling towers  
568 against *Legionella pneumophila*. *Chemotherapy* 54:107-16.
- 569 37. **Lai NM, Chaiyakunapruk N, Lai NA, O'Riordan E, Pau WS, Saint S.** 2016.  
570 Catheter impregnation, coating or bonding for reducing central venous catheter-related  
571 infections in adults. *Cochrane Database Syst Rev* 3:CD007878.
- 572 38. **Bloomfield SF.** 2007. Importance of disinfection as a means of prevention in our  
573 changing world hygiene and the home. *GMS Krankenhhyg Interdiszip* 2:Doc25.
- 574 39. **Aiello AE, Marshall B, Levy SB, Della-Latta P, Larson E.** 2004. Relationship  
575 between triclosan and susceptibilities of bacteria isolated from hands in the community.  
576 *Antimicrob Agents Chemother* 48:2973-9.
- 577 40. **McBain AJ, Ledder RG, Sreenivasan P, Gilbert P.** 2004. Selection for high-level  
578 resistance by chronic triclosan exposure is not universal. *J Antimicrob Chemother*  
579 53:772-7.
- 580 41. **Kümmerer K, Eitel A, Braun U, Hubner P, Daschner F, Mascart G, Milandri M,**  
581 **Reinthal F, Verhoef J.** 1997. Analysis of benzalkonium chloride in the effluent from  
582 European hospitals by solid-phase extraction and high-performance liquid  
583 chromatography with post-column ion-pairing and fluorescence detection. *Journal of*  
584 *chromatography A* 774:281-286.
- 585 42. **Reinthal F, Posch J, Feierl G, Wüst G, Haas D, Ruckebauer G, Mascher F,**  
586 **Marth E.** 2003. Antibiotic resistance of *E. coli* in sewage and sludge. *Water Research*  
587 37:1685-1690.
- 588 43. **Bore E, Hebraud M, Chafsey I, Chambon C, Skjaeret C, Moen B, Moretto T,**  
589 **Langsrud O, Rudi K, Langsrud S.** 2007. Adapted tolerance to benzalkonium chloride  
590 in *Escherichia coli* K-12 studied by transcriptome and proteome analyses. *Microbiology*  
591 153:935-46.
- 592 44. **Martinez-Carballo E, Sitka A, Gonzalez-Barreiro C, Kreuzinger N, Furhacker M,**  
593 **Scharf S, Gans O.** 2007. Determination of selected quaternary ammonium compounds  
594 by liquid chromatography with mass spectrometry. Part I. Application to surface, waste  
595 and indirect discharge water samples in Austria. *Environ Pollut* 145:489-96.
- 596 45. **Martinez-Carballo E, Gonzalez-Barreiro C, Sitka A, Kreuzinger N, Scharf S, Gans**  
597 **O.** 2007. Determination of selected quaternary ammonium compounds by liquid  
598 chromatography with mass spectrometry. Part II. Application to sediment and sludge  
599 samples in Austria. *Environ Pollut* 146:543-7.
- 600 46. **Mechin L, Dubois-Brissonnet F, Heyd B, Leveau JY.** 1999. Adaptation of  
601 *Pseudomonas aeruginosa* ATCC 15442 to didecyldimethylammonium bromide induces  
602 changes in membrane fatty acid composition and in resistance of cells. *J Appl Microbiol*  
603 86:859-66.
- 604 47. **Heir E, Sundheim G, Holck AL.** 1999. The *qacG* gene on plasmid pST94 confers  
605 resistance to quaternary ammonium compounds in staphylococci isolated from the food  
606 industry. *J Appl Microbiol* 86:378-88.

- 607 48. **Ceragioli M, Mols M, Moezelaar R, Ghelardi E, Senesi S, Abee T.** 2010.  
608 Comparative transcriptomic and phenotypic analysis of the responses of *Bacillus cereus*  
609 to various disinfectant treatments. *Appl Environ Microbiol* 76:3352-60.
- 610 49. **Langsrud S, Sundheim G, Holck AL.** 2004. Cross-resistance to antibiotics of  
611 *Escherichia coli* adapted to benzalkonium chloride or exposed to stress-inducers. *J Appl*  
612 *Microbiol* 96:201-8.
- 613 50. **Bore E, Hebraud M, Chafsey I, Chambon C, Skjæret C, Moen B, Møretrø T,**  
614 **Langsrud Ø, Rudi K, Langsrud S.** 2007. Adapted tolerance to benzalkonium chloride  
615 in *Escherichia coli* K-12 studied by transcriptome and proteome analyses. *Microbiology*  
616 153:935-946.
- 617 51. **Moen B, Rudi K, Bore E, Langsrud S.** 2012. Subminimal inhibitory concentrations of  
618 the disinfectant benzalkonium chloride select for a tolerant subpopulation of  
619 *Escherichia coli* with inheritable characteristics. *International journal of molecular*  
620 *sciences* 13:4101-4123.
- 621 52. **Gilbert P, Moore LE.** 2005. Cationic antiseptics: diversity of action under a common  
622 epithet. *J Appl Microbiol* 99:703-15.
- 623 53. **Girón JA, Torres AG, Freer E, Kaper JB.** 2002. The flagella of enteropathogenic  
624 *Escherichia coli* mediate adherence to epithelial cells. *Molecular microbiology* 44:361-  
625 379.
- 626 54. **Pratt LA, Kolter R.** 1998. Genetic analysis of *Escherichia coli* biofilm formation:  
627 roles of flagella, motility, chemotaxis and type I pili. *Molecular microbiology* 30:285-  
628 293.
- 629 55. **Farkas A, Craciunas C, Chiriac C, Szekeres E, Coman C, Butiuc-Keul A.** 2016.  
630 Exploring the Role of Coliform Bacteria in Class 1 Integron Carriage and Biofilm  
631 Formation During Drinking Water Treatment. *Microb Ecol* 72:773-782.
- 632 56. **Chin CY, Tipton KA, Farokhyfar M, Burd EM, Weiss DS, Rather PN.** 2018. A  
633 high-frequency phenotypic switch links bacterial virulence and environmental survival  
634 in *Acinetobacter baumannii*. *Nat Microbiol* 3:563-569.
- 635 57. **Gillings MR, Gaze WH, Pruden A, Smalla K, Tiedje JM, Zhu YG.** 2015. Using the  
636 class 1 integron-integrase gene as a proxy for anthropogenic pollution. *ISME J* 9:1269-  
637 79.
- 638 58. **Earle SG, Wu CH, Charlesworth J, Stoesser N, Gordon NC, Walker TM, Spencer**  
639 **CCA, Iqbal Z, Clifton DA, Hopkins KL, Woodford N, Smith EG, Ismail N,**  
640 **Llewelyn MJ, Peto TE, Crook DW, McVean G, Walker AS, Wilson DJ.** 2016.  
641 Identifying lineage effects when controlling for population structure improves power in  
642 bacterial association studies. *Nat Microbiol* 1:16041.
- 643 59. **Forbes S, Latimer J, Bazaid A, McBain AJ.** 2015. Altered Competitive Fitness,  
644 Antimicrobial Susceptibility, and Cellular Morphology in a Triclosan-Induced Small-  
645 Colony Variant of *Staphylococcus aureus*. *Antimicrobial Agents and chemotherapy*  
646 59:4809-4816.
- 647 60. **Martin M.** 2011. Cutadapt removes adapter sequences from high-throughput  
648 sequencing reads. *EMBnet journal* 17:pp. 10-12.
- 649 61. **Langmead B, Salzberg SL.** 2012. Fast gapped-read alignment with Bowtie 2. *Nature*  
650 *methods* 9:357-359.
- 651 62. **Blattner FR, Plunkett G, 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-**  
652 **Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick**  
653 **HA, Goeden MA, Rose DJ, Mau B, Shao Y.** 1997. The complete genome sequence of  
654 *Escherichia coli* K-12. *Science* 277:1453-62.

655

656

657



658

659

660 **FIG 1** *E. coli* planktonic growth after 10 or 20 passages in the absence or presence of BAC. *E. coli* was  
661 passaged 10 (P 10) and 20 (P20) times in binary culture in the presence of 100 ng/L (B100) or 1000  
662 ng/L (B1000) of BAC prior to determination of planktonic growth. Control cultures prior to passage (C  
663 P0) or passaged in a BAC-free environment over 10 and 20 passages were included (C (P10) and C  
664 (P20) respectively). Data represent two separate experiments each with three technical replicates Error  
665 bars are representative of standard deviations.

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681


682

683

684


685

686




687

688 **FIG 2** Crystal violet assay indicating biofilm formation (OD<sub>600</sub>) before (control; C (P0)) and after 10 or  
 689 20 passages in the absence (C (P10) and C (P20) or the presence of 100 ng/L of BAC (B100 P10/20) or  
 690 1000 ng/L of BAC (B1000 P10/20). Error bars represent standard deviations. Data represent two  
 691 separate experiments each with three technical replicates. Biofilm formation was significantly ( $p < 0.05$ )  
 692 reduced following exposure to residual concentrations of BAC (C (P10)) and (C (P20)). This was the  
 693 case for exposure 100 ng/L and 1000ng/L BAC after 10 and 20 passages. Exposure to BAC at 1000  
 694 ng/L for 10 passages resulted in significantly lower biofilm formation than 10 passages with 100 ng/L of  
 695 BAC. Following 20 passage exposures differences for 100 and 1000ng/L BAC were not statistically  
 696 significant.



**FIG 3** PCA plot indicating variation in DE genes for *E. coli* when comparing an unpassed control bacterium C0, a bacterium passaged 20 times in a BAC-free environment (C20) and a bacterium passaged 20 times in the presence of 100 ng/L BAC (B 20). C0 (black), C20 (green) and B20 (cyan) were grown in biocide free-media prior to RNA extraction whilst C0P (red), C20P (dark blue) and B20P (pink) indicate bacteria that were grown in the presence of BAC immediately prior to RNA extraction. This allowed us to determine whether any changes in the transcriptome were maintained when BAC was removed from the growth medium. Data are derived from three biological replicates for each bacterium.

752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779



780 **FIG 4** Motility before (C (P0)) and after 20 passages in binary culture in the absence (C (P20)) or  
781 presence (B (P20)) of 100 ng/L BAC.

782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804

805 **TABLE 1** *E. coli* MICs and MBCs before (P0) and after 10 (P10)  
 806 and 20 (P20) passages in residual concentrations of BAC

|          | MIC (µg/ml) |     |     | MBC (µg/ml) |     |            |
|----------|-------------|-----|-----|-------------|-----|------------|
|          | P0          | P10 | P20 | P0          | P10 | P20        |
|          | Control     | 50  | 50  | 50          | 50  | 50         |
| BAC 100  | 50          | 50  | 50  | 50          | 50  | <b>100</b> |
| BAC 1000 | 50          | 50  | 50  | 50          | 50  | <b>100</b> |

817 Data show the mean minimum inhibitory concentrations and minimum  
 818 bactericidal concentrations of bacteria before and after BAC exposure  
 819 and represent samples taken from two separate experiments each  
 820 with three technical replicates (values did not vary between replicates).  
 821 Control refers to the unpassaged bacterium. P, passage. Bold text  
 822 indicates  $\geq 2$ -fold changes when comparing P0 to P10 or P20.  
 823

824

825

826

827

828

829

830

831

832

833

834

835

836 **TABLE 2** Differentially expressed genes associated with electron transport

| Gene | Gene product                                  | logFC        | logFC         | logFC           |
|------|---|--------------|---------------|-----------------|
|      |   | C20 $\nu$ C0 | B20 $\nu$ C20 | B20P $\nu$ C20P |
| cyoA | Cytochrome o oxidase subunit a                | 4.96         | -3.90         | -3.81           |
| cyoB | Cytochrome o oxidase subunit b                | 4.27         | -3.54         | -2.68           |
| cyoC | Cytochrome o oxidase subunit c                | 4.53         | -3.87         | -2.82           |
| cyoD | Cytochrome o oxidase subunit d                | 3.50         | -2.68         | -3.81           |
| cyoE | Cytochrome o oxidase subunit e                | 3.42         | -3.46         | -3.41           |
| fdoH | Formate dehydrogenase-O iron-sulfur subunit   | 3.81         | -2.39         | -2.12           |
| fdoI | Formate dehydrogenase cytochrome b556 subunit | 2.72         | -3.44         | -3.09           |
| fdoG | Formate dehydrogenase-O major subunit         | 4.18         | -3.69         | -3.55           |
| nuoA | NADH-quinone oxidoreductase subunit A         | 2.36         | -2.49         | -1.89           |
| nuoB | NADH-quinone oxidoreductase subunit B         | 3.25         | -2.92         | -2.21           |
| nuoC | NADH-quinone oxidoreductase subunit C         | 3.08         | -2.68         | -2.30           |
| nuoE | NADH-quinone oxidoreductase subunit E         | 3.21         | -2.51         | -2.26           |
| nuoF | NADH-quinone oxidoreductase subunit F         | 3.16         | -2.69         | -2.09           |
| nuoG | NADH-quinone oxidoreductase subunit G         | 3.20         | -3.13         | -2.56           |
| nuoH | NADH-quinone oxidoreductase subunit H         | 2.72         | -2.81         | -2.21           |
| nuoI | NADH-quinone oxidoreductase subunit I         | 2.70         | -2.61         | -1.92           |
| nuoJ | NADH-quinone oxidoreductase subunit J         | 2.24         | -2.23         | -1.90           |
| nuoK | NADH-quinone oxidoreductase subunit K         | 2.27         | Ns            | -2.25           |
| nuoL | NADH-quinone oxidoreductase subunit L         | 2.05         | Ns            | -1.71           |
| nuoM | NADH-quinone oxidoreductase subunit M         | 2.66         | -1.91         | -2.20           |
| nuoN | NADH-quinone oxidoreductase subunit N         | 1.80         | -2.21         | -1.44           |

837  
838 Differentially expressed genes in in *Escherichia coli* after repeated passage in a BAC free (C20 to C0)  
839 and BAC at 100ng/L (B20 to C20 and B20P to C20P). Data represent three biological repeats.  $\nu$ , versus.  
840

841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851

852 **TABLE 3** Differentially expressed genes associated with outer membrane permeability and efflux

| Gene | Gene product                     | logFC<br>C20 v C0 | logFC<br>B20 v C20 | logFC<br>B20P v C20P |
|------|----------------------------------|-------------------|--------------------|----------------------|
| tolC | Outer membrane protein           | 1.14              | -1.22              | ns                   |
| ompA | Outer membrane protein A         | ns                | -1.35              | ns                   |
| ompC | Outer membrane protein C         | ns                | -1.85              | ns                   |
| ompF | Outer membrane protein F         | ns                | -2.18              | -1.70                |
| ompG | Outer membrane protein G         | ns                | 3.02               | ns                   |
| ompL | Outer membrane protein L         | ns                | 3.40               | ns                   |
| ompN | Outer membrane protein N         | ns                | 3.13               | ns                   |
| ompT | Outer membrane protein T         | ns                | -1.62              | -1.38                |
| ompR | Outer membrane protein R         | 0.93              | -0.89              | -0.86                |
| ompX | Outer membrane protein X         | ns                | -1.88              | ns                   |
| ompW | Outer membrane protein W         | ns                | -2.19              | -2.29                |
| acrA | Multidrug efflux pump subunit    | 1.44              | -1.04              | ns                   |
| acrD | Aminoglycoside efflux pump       | na                | 0.92               | 0.84                 |
| mdtE | Multidrug resistance protein     | 2.46              | 4.13               | 3.24                 |
| mdtF | Multidrug resistance protein     | 1.32              | 1.92               | 0.97                 |
| mdtJ | Multidrug resistance protein     | 1.50              | ns                 | ns                   |
| mdtG | Multidrug resistance protein     | ns                | 1.63               | ns                   |
| mdtL | Multidrug resistance protein     | ns                | 2.13               | ns                   |
| mdtM | Multidrug resistance protein     | ns                | 2.05               | ns                   |
| mdtN | Multidrug resistance protein     | 3.16              | 4.40               | ns                   |
| mdtO | Multidrug resistance protein     | 2.55              | 3.99               | 2.78                 |
| mdtP | Multidrug resistance protein     | 2.51              | 3.66               | 2.46                 |
| mdtQ | Multidrug resistance protein     | 2.58              | 3.51               | ns                   |
| yhiD | Putative magnesium transporter   | 2.48              | 3.24               | 2.72                 |
| yhiJ | Putative uncharacterised protein | 3.13              | 3.88               | 2.93                 |
| yhiM | Inner membrane protein           | 2.38              | 3.39               | 2.37                 |
| yhiL | Putative uncharacterised protein | 3.56              | 4.37               | 3.83                 |
| yhiS | Putative uncharacterised protein | 3.90              | 4.88               | 3.95                 |

853 <sup>a</sup> See footnote to Table 2. ns, no significant change.

854

855

856

857

858

859

860

861

862

863

864

865 **TABLE 4** Differentially expressed genes associated with motility

| Gene | Gene product                                 | logFC    | logFC     | logFC       |
|------|--|----------|-----------|-------------|
|      |  | C20 v C0 | B20 v C20 | B20P v C20P |
| fliA | RNA polymerase sigma factor                  | ns       | -6.07     | -7.16       |
| fliC | Flagellin                                    | 3.46     | -6.69     | -6.60       |
| fliD | Flagellar hook-associated protein 2          | 2.00     | -3.41     | -4.53       |
| fliE | Flagellar hook-basal body complex protein    | ns       | -4.42     | -5.66       |
| fliF | Flagellar M-ring protein                     | ns       | -6.46     | -7.63       |
| fliG | Flagellar motor switch protein               | ns       | -5.67     | -6.99       |
| fliH | Flagellar assembly protein                   | 1.12     | -6.20     | -7.29       |
| fliI | Flagellum-specific ATP synthase              | ns       | -5.86     | -7.16       |
| fliJ | Flagellar protein                            | 1.22     | -5.16     | -5.64       |
| fliK | Flagellar hook-length control protein        | ns       | -4.06     | -5.06       |
| fliL | Flagellar protein                            | ns       | -6.97     | -7.84       |
| fliM | Flagellar motor switch protein               | ns       | -5.64     | -6.22       |
| fliN | Flagellar motor switch protein               | ns       | -6.38     | -6.72       |
| fliO | Flagellar protein                            | ns       | -5.74     | -5.97       |
| fliP | Flagellar biosynthetic protein               | ns       | -4.47     | -5.89       |
| fliQ | Flagellar biosynthetic protein               | ns       | -4.38     | -5.02       |
| fliS | Flagellar secretion chaperone                | 2.30     | -4.72     | -5.76       |
| fliT | Flagellar protein                            | ns       | -3.05     | -3.46       |
| fliZ | Regulator of sigma S factor                  | ns       | -3.79     | -4.48       |
| flgA | Flagella basal body P-ring formation protein | ns       | -5.71     | -5.78       |
| flgB | Flagellar basal body rod protein             | 2.39     | -6.99     | -8.56       |
| flgC | Flagellar basal-body rod protein             | 2.33     | -7.86     | -7.74       |
| flgD | Basal-body rod modification protein          | 2.17     | -6.72     | 0.00        |
| flgE | Flagellar hook protein                       | 2.48     | -5.96     | -6.82       |
| flgF | Flagellar basal-body rod protein             | 2.26     | -6.89     | -7.17       |
| flgG | Flagellar basal-body rod protein             | 2.36     | -5.64     | -6.33       |
| flgH | Flagellar L-ring protein                     | 1.98     | -5.20     | -6.03       |
| flgI | Flagellar P-ring protein                     | 1.77     | -5.64     | -6.22       |
| flgJ | Peptidoglycan hydrolase                      | 1.20     | -5.55     | -5.93       |
| flgK | Flagellar hook-associated protein 1          | 2.11     | -5.85     | 0.00        |
| flgL | Flagellar hook-associated protein 3          | 1.75     | -5.69     | -6.05       |
| flgN | Flagella synthesis protein                   | 1.60     | -5.76     | -6.50       |
| flhA | Flagellar biosynthesis protein               | ns       | -4.45     | -4.76       |
| flhB | Flagellar biosynthetic protein               | ns       | -5.38     | -6.17       |
| flhC | Flagellar transcriptional regulator          | ns       | -5.37     | -5.99       |
| flhD | Flagellar transcriptional regulator          | ns       | -2.55     | -2.51       |
| flhE | Flagellar protein                            | ns       | -4.65     | -5.08       |
| motA | Motility protein A                           | ns       | -7.13     | -7.83       |
| motB | Motility protein B                           | ns       | -5.27     | -6.11       |

866 <sup>a</sup> See footnote to Tables 2 and 3.

867

868

869

870

871 **TABLE 5** Differentially expressed genes associated with chemotaxis

| Gene | Gene product                          | logFC    | logFC     | logFC       |
|------|---------------------------------------|----------|-----------|-------------|
|      |                                       | C20 v C0 | B20 v C20 | B20P v C20P |
| tsr  | Methyl-accepting chemotaxis protein   | 2.57     | -6.34     | -7.05       |
| tar  | Methyl-accepting chemotaxis protein   | 1.69     | -6.46     | -5.57       |
| tap  | Methionine import ATP-binding protein | 1.98     | -4.94     | -6.09       |
| cheR | Chemotaxis protein methyltransferase  | ns       | -3.52     | -4.67       |
| cheZ | Protein phosphatase                   | ns       | -5.77     | -5.96       |
| cheA | Chemotaxis protein                    | ns       | -5.20     | -6.11       |
| cheR | Chemotaxis protein methyltransferase  | ns       | -3.52     | -4.67       |
| cheB | Protein-glutamate methylesterase      | ns       | -6.01     | -6.41       |
| cheY | Chemotaxis protein                    | ns       | -6.19     | -6.94       |
| cheW | Chemotaxis protein                    | ns       | -6.54     | -6.97       |

872 <sup>a</sup> See footnote to Tables 2 and 3.

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889